A phase Ib study in newly diagnosed glioblastoma reported results for a personalized neoantigen-pulsed, autologous dendritic cell vaccine approach, published in Nature Communications. The regimen uses patient-specific neoantigen selection and dendritic cell preparation to drive T-cell responses against tumor antigens. The trial is positioned as an early clinical signal for feasibility and immunogenicity in a setting where effective immunotherapies remain limited. For clinicians, the key near-term question is whether the approach can generate durable immune pressure within the glioblastoma microenvironment. With personalized vaccines, manufacturing timelines and antigen selection are often major bottlenecks; the report centers on clinical experience with the platform and how it translated into measurable immune activity in patients. If the data continue to support safety and response durability, the program could influence next-generation glioblastoma vaccine designs and combination strategies with checkpoint inhibition and other immunomodulators.